IPBronch.com | Interventional Pulmonology

🎯 Background & Rationale

Subsolid nodules (SSNs) and ground-glass opacities (GGOs) represent a diagnostic dilemma in clinical practice because they span a spectrum from benign inflammatory processes to indolent pulmonary adenocarcinomas. While many guidelines recommend conservative radiographic observation, uncertainty remains regarding optimal surveillance intervals, natural history of growth, solid transformation rates, and true disease-specific mortality. Furthermore, much of the existing literature is derived from Asian cohorts, raising questions about generalizability to North American populations with differing smoking histories and tumor biology. This study aims to define the natural history, treatment likelihood, survival rates, and causes of mortality in a comprehensive North American healthcare system cohort of patients with SSNs and GGOs.

👥 Study Design & Population

Study Type: Retrospective Cohort Study

Population: Adults (ages 35-99) within the Yale New Haven Health System who underwent an outpatient chest CT scan in 2017 and were identified via natural language processing (NLP) to have incidental or screened subsolid nodules/ground-glass opacities.
Intervention / Exposure: Radiographic surveillance vs. treatment (surgical resection, SBRT, or ablation) of dominant SSNs (nonsolid vs. part-solid).
Comparison: Nonsolid nodules (pure GGOs) compared against part-solid nodules regarding growth, solid transformation, and treatment rates.
Outcomes: 5-year overall survival, cancer-specific survival, SSN-specific survival, solid component transformation, growth trajectories, and incidence of second primary malignancies.

📈 Methodology & Rigor

The authors utilized natural language processing (mPower Clinical Analytics) across 17,276 chest CT reports from 2017 to identify 1,052 initial scans containing SSN terminology. Following manual chart review, exclusions were made for metastatic disease, active infection, benign inflammatory etiologies, or lack of follow-up, yielding a final study cohort of 322 patients. Radiographic growth was strictly defined as ≥ 2 mm in any dimension. Statistical analyses included χ² and $t$ tests for demographic/radiographic comparisons, and Kaplan-Meier methods for survival and time-to-treatment evaluations. While retrospective and subject to non-standardized individual clinical decision-making rather than a strict trial protocol, the use of a broad healthcare system database successfully minimized referral and nodule-registry biases.

🔬 Key Findings

Baseline Cohort Breakdown: Of the 322 patients, 64% (n = 207) had nonsolid (pure GGO) nodules and 36% (n = 115) had part-solid nodules.
Natural History & Growth (5-Year Follow-up):
- Among nonsolid nodules, 81% remained pure nonsolid, while 19% developed a new solid component.
- Approximately 40% of both nonsolid and part-solid nodules grew ≥ 2 mm in ground-glass size over 5 years.
Treatment Rates: Only 19% (n = 60) of the overall cohort underwent treatment within 5 years. Part-solid nodules were significantly more likely to be treated than nonsolid nodules (32% vs. 11%, P < .001). Nodules ≥ 2 cm had a significantly higher 5-year likelihood of treatment compared to those < 2 cm (44.8% vs. 17.6%).
Survival & Competing Mortality:
- 5-year overall survival was 79.8%.
- SSN-related mortality was exceedingly rare at 1.54% (5-year SSN-related survival of 98.4%).
- Patients were significantly more likely to develop and die from an unrelated second primary cancer than from their SSN (8.43% vs. 1.54%, P < .001).
Second Primary Malignancies: Treated patients demonstrated a 31.2% cumulative incidence of requiring treatment for a second lung primary or separate SSN within 5 years.

⚖️ Critical Appraisal

Internal Validity: The retrospective nature of the study lacks a standardized treatment or surveillance protocol, leaving intervention decisions up to individual clinicians and tumor boards. Additionally, nearly 20% of initially identified patients were excluded due to lack of follow-up data.
External Validity: The cohort is predominantly Caucasian (87%) with a high prevalence of prior tobacco exposure (81%), reflecting a North American demographic. While this makes the data highly applicable to Western clinical populations, findings cannot be directly extrapolated to Asian screening cohorts with distinct genetic and epidemiological risk profiles (e.g., higher never-smoker EGFR mutation prevalence).
Strengths: Avoids the referral bias inherent in surgical or nodule-registry studies by capturing a real-world, unselected healthcare system cohort via NLP.

💡 The Clinical Bottom Line

For the interventional pulmonologist and bronchoscopist, this study reinforces that pure ground-glass opacities and small subsolid nodules are overwhelmingly indolent and can safely undergo long-term radiographic surveillance without immediate intervention. Clinicians should aggressively reassure patients regarding the exceptionally low mortality risk directly attributable to an SSN (~1.5%). Instead, management must shift focus toward vigilant surveillance for parenchymal preservation (favoring wedge/segmental resections or ablation when intervention is truly indicated) and whole-patient screening for unrelated second primary lung cancers and non-pulmonary malignancies, which pose a vastly greater mortality threat than the index SSN.

BACKGROUND: Subsolid nodules (SSNs) and ground glass opacities (GGOs) are an increasingly common clinical problem. This unique subtype of lung adenocarcinoma poses a treatment dilemma as many can be safely monitored with radiographic observation alone and require no intervention. Improved understanding of the natural history and outcomes of patients with subsolid nodules is needed to improve clinical decision making and treatment recommendations. RESEARCH QUESTION: What is the natural history of growth, likelihood of treatment, and most likely cause of mortality in a comprehensive cohort of patients with subsolid nodules and ground glass opacities identified on chest CT scan? STUDY DESIGN AND METHODS: Natural language processing was used to identify all patients with subsolid nodules on outpatient chest CT scans in 2017 (n=17,276) in the Yale New Haven Health system. Manual chart review was performed for demographics, nodule size, growth on subsequent CT, treatment, pathology, and survival. RESULTS: A cohort of 322 patients were identified with 64% (n=207) non-solid nodules (pure GGO) and 36% (n=115) part-solid nodules. Over 5-years of follow-up, 81% of non-solid nodules remained non-solid and 19% developed a new solid component. Within 5-years, 19% (n=60) underwent treatment, with patients with part-solid nodules being more likely to undergo treatment than those with non-solid nodules (32% vs 11%, p<0.001). Five-year overall survival was 79.8%, with 98.4% 5-year subsolid nodule-related survival. Development of a new, second primary malignancy was common in SSN-patients, who were significantly more likely to die from a secondary primary cancer than their subsolid nodule at 5-years (8.43% vs 1.54%, p<0.001). INTERPRETATION: Patients should be reassured regarding the excellent survival associated with subsolid nodules. Most can be safely observed without intervention, particularly non-solid nodules or pure GGOs. Patients with subsolid nodules have high rates of developing multiple lung nodules and second primary lung cancer.